Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism

Imagem de Miniatura



Título da Revista

ISSN da Revista

Título de Volume



From the identification of HIV as the agent causing AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research over the past twenty-six years have been formidable. Currently, there are twenty-five anti-HIV compounds which have been formally approved for clinical use in the treatment of AIDS. These compounds fall into six categories: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), cell entry inhibitors or fusion inhibitors (FIs), co-receptor inhibitors (CRIs), and integrase inhibitors (INIs). Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. Formation of active or toxic metabolites will also have an impact on the pharmacological and toxicological outcomes. Therefore, it is widely recognized that metabolism studies of a new chemical entity need to be addressed early in the drug discovery process. This paper describes an overview of the metabolism of currently available anti-HIV drugs.



Biotransformation, AIDS, Drugs, Antiretroviral drugs, Biotransformação, Anti-HIV, Antirretrovirais


ANDRADE, Carolina Horta; FREITAS, Lenis Medeiros de; OLIVEIRA, Valéria de. Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism. Revista Brasileira de Ciências Farmacêuticas, São Paulo, v. 47, n. 2, p. 209-230, 2011.